Última actualização :
19/11/2024
droga contra o câncer   Epirubicin hydrochloride  
injetável
Estabilidade em soluções simples Estabilidade em misturas Factores que afectam a sua estabilidade Compatibilidade Método de administração Bibliografía pdf
   estrutura química  

Nomes comerciais nos diversos países   Nomes comerciais nos diversos países     

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Anthracine Malásia
Axirubicine Alemanha
Bendaepi Alemanha
Binarin México
Bioepycina Polonia
Crisabon Argentina
Cuatroepi Argentina
Ecclepia Romènia
Elebicin México
Ellence Estados Unidos de América
Epi Cell Alemanha
Epidoxo Argentina, Chilli, Venezuela
Epifil Equator
Epilem Colômbia, México
Epimedac Alemanha
Epirubicin Arábia Saudita, Australia, Austria, Bélgica, Dinamarca, Gran-bretanha, Hungria, Islandia, nova Zelândia, Suècia, Suicia, Turquia
Epirubicina Argentina, Colômbia, Equator, Espanha, México, Romènia
Epirubicine Bélgica, França, Suicia
Farmarubicin Turquia
Farmorubicin Arábia Saudita, Austria, Brasil, Dinamarca, Finlandia, Grècia, Noruega, Suècia, Suicia
Farmorubicin CSV Africa do sul
Farmorubicin PFS Croácia, Eslovenia, Polonia
Farmorubicin RD Brasil, Polonia, russo, Suicia
Farmorubicin RTU Países Baixos
Farmorubicina Brasil, Espanha, Itália, Portugal
Farmorubicine Bélgica, França
Pharmorubicin Gran-bretanha
Bibliografía   injetável   Bibliografía : Epirubicin hydrochloride  
tipo publicação
148 jornal Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I.
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.
Pharm Weekbl [Sci] 1992 ; 14: 365-369.
525 jornal De Vroe C, De Muynck C, Remon JP, Samsom M.
A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters.
Int J Pharm 1990 ; 65: 49-56.
683 jornal Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C.
Epirubicin stability in syringes and glass vials and evaluation of chemical contamination.
Can J Hosp Pharm 1990 ; 43: 265-272.
686 jornal Wood MJ, Irwin WJ, Scott DK.
Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags.
J Clin Pharm Ther 1990 ; 15: 279-289.
887 jornal Pujol M, Munoz M, Prat J, Giona V, De Bolos J.
Stability study of epirubicin in NaCl 0.9% injection.
Ann Pharmacotherapy 1997 ; 31: 992-995.
1237 jornal Keusters L, Stolk LML, Umans R, Van Asten P.
Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation.
Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265 jornal Wood MJ, Irwin WJ, Scott DK.
Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography.
J Clin Pharm Ther 1990 ; 15: 291-300.
1317 jornal Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG.
Pharmaceutical aspects of home infusion therapy for cancer patients.
Pharm J 1987 ; 238: 476-478.
1662 jornal Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1823 jornal Sewell GJ, Rigby-Jones AE, Priston MJ.
Stability of intravesical epirubicin infusion: a sequential temperature study.
J Clin Pharm Ther 2003 ; 28: 349-353.
1897 jornal Sautou-Miranda V, Brigas F, Thibault M, Chopineau J.
Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage.
EJHP 2001 ; 7, 3: 108-115.
1955 jornal Trissel LA, Zhang Y.
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Ann Pharmacotherapy 2005 ; 39: 280-283.
2168 jornal Ozdemir FA, Anilanmert B, Pekin M.
Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution.
Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2257 Laboratório Stability of epirubicin "Ebewe" infusion solutions.
Ebewe Pharma 2007
3473 jornal Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B.
Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization.
Int J Pharm 2015 ; 495, 2: 956-962.
3474 Laboratório Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3632 Laboratório Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics
Hospira 2017
3670 jornal Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3708 poster Sarakbi I, Thiesen J, Krämer I.
Compatibility of epirubicin-loaded DC Beads with different contrast media.
ECOP 2 Krakow 2014
3918 jornal Sarakbi I, Krämer I.
Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media.
J Oncol Pharm Practice 2016 ; 22: 749-756.
4352 jornal Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y.
In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag.
J Clin Pharm Ther 2019 ; 44: 875-882.

  Mentions Légales